39 filings
Page 2 of 2
8-K
cba8d 1rt0qf8
10 Mar 23
Entry into a Material Definitive Agreement
7:51am
8-K
w6m3upet9yjgz08m5je
22 Feb 23
Cognition Therapeutics and ACTC Receive FDA Clearance for Phase 2 START Study of Oral CT1812 in Early Alzheimer’s Disease
8:14am
8-K
de7hgy5hkk4g0th
13 Feb 23
Other Events
8:00am
8-K
z7sgwa rbv
23 Dec 22
Entry into a Material Definitive Agreement
4:24pm
8-K
559hlpuz3ziltqj3e5
16 Nov 22
Developing disease - modifying medicines for degenerative disorders November 2022
5:18pm
8-K
8i283gj
14 Nov 22
Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
8:00am
8-K
chths
29 Aug 22
Developing disease- modifying medicines for degenerative disorders August 2022
6:36am
8-K
cv42sfeim31lu352fz
9 Aug 22
Cognition Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
7:15am
8-K
fc8kx4
27 Jul 22
Departure of Directors or Certain Officers
4:30pm
8-K
iwi28r1kes9rsg84gun
16 Jun 22
Regulation FD Disclosure
7:08am
8-K
7iq2t
13 Jun 22
Submission of Matters to a Vote of Security Holders
5:07pm
8-K
kfnyhxokg h3dqm
11 May 22
Cognition Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
7:06am
8-K
9vs97bk32lq962e3t9j4
30 Mar 22
Cognition Therapeutics Reports Year End 2021 Financial Results and Provides
7:29am
8-K
rbhmj7 02uq6ra
15 Mar 22
Regulation FD Disclosure
9:32am
8-K
w0vj2jj
10 Jan 22
Regulation FD Disclosure
7:01am
8-K
3v8i9ss3e uex3uv307
18 Nov 21
Cognition Therapeutics Reports Third Quarter Financial Results and Company Highlights
8:30am
8-K
454l7bjqk081lfi2
12 Nov 21
Regulation FD Disclosure
5:20pm
8-K
v29iupy7x17kk uz
3 Nov 21
Departure of Directors or Certain Officers
4:25pm
8-K
d4czsnk lczm81dng
14 Oct 21
Amendments to Articles of Incorporation or Bylaws
4:41pm